Spending like a bigger company on purpose: current results carry the cost of an expansion aimed at demand management say
The model's full reasoning — Q1 2016 call → NOThe question asks whether management acknowledges that current results are weighed down by an expansion already undertaken, and whether they justify it by pointing to demand that is already real. Let me analyze the transcript: 1. Expansion already underway and visibly costing something now: - Jim Dentzer (CFO) discusses R&D expenses increasing from $4.7M to $6.8M, "primarily due to increased direct spending related to outside services supporting the ongoing clinical activities of CUDC-907, including initial costs for the Phase 2 trial that was initiated in January 2016 and direct costs for programs under the Aurigene collaboration over the prior-year period. Finally, employee related expenses increased over the prior-year primarily due to increased headcount." - Ali Fattaey mentions "David Tuck, who is our recently appointed Chief Medical Officer... David has been growing the organization in terms of clinical development, including additional MDs that have recently joined him and I think majority of our increased headcount or increased expertise... is all in the clinical development area." - He also mentions "we certainly see us heading fairly heavily into the diagnostic arena... That's an area of expertise that we certainly look at very strongly in the organization to continue to bolster." So there is hiring and spending described. But does management acknowledge this is "weighing down" current results? The CFO describes the increased R&D spending as due to clinical activities and headcount. The net loss is $9.4M. But is this described as a deliberate expansion that is depressing current profitability? The CFO just reports the numbers without framing it as a burden. The CEO describes growing the organization in clinical development and diagnostics. 2. Justification by demand already real: - For CUDC-907: The Phase 2 trial is ongoing, enrolling patients with MYC alterations. The justification is based on Phase 1 data showing responses correlated with MYC alterations. This is clinical trial data, not "demand" in a commercial sense. - For CA170: It's about to enter the clinic. The justification is the market for PD1 inhibitors being multibillion-dollar, but that's market forecasts, not demand already in hand. - For Erivedge: Roche initiated two new studies, but that's not demand for Curis's expansion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
SIBN · Q3 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken — spending, hirin...YES Management explicitly describes the expansion as already underway and costing the company now: investments in sales force (85 territory managers + 72 specialists), new products (iFuse-TORQ, iFuse-Bedrock Granite), instrument trays, inventory, and R&D that are driving higher depreciation, freight, and product costs 84% gross margin (down low-single digits from these factors). Anshul confirms “we’ve made a substantial amount of investment whether it’s in TORQ trays or Granite trays or TORQ implants” and “this is going to lead to elevated depreciation,” while Laura notes the build supports “strong new product demand.
FLYW · Q1 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES The transcript shows management explicitly linking the current EBITDA decline to the hiring expansion already completed ("increased the number of FlyMates by over 50% during the past year" and "added over 100 new FlyMates within the sales, marketing and product functions"), while framing the spending as a deliberate, ongoing 2022 investment plan that is already delivering observable results through record client adds (130), pipeline growth, and strong ARR signings.
EVGO · Q2 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES Management describes concrete expansion already underway—170 stalls placed in Q2, total stalls at 2,397 with 460 under construction, pipeline at 3,669, CapEx jumped to $44 million to accelerate deployment, and G&A ramping personnel to support growth—while directly tying the resulting negative adjusted EBITDA of -$19.8 million to that deliberate build-out.